Last week, the judge heard arguments in a case that will decide the safety of mifepristone, one of the drugs in the two-pill regimen that has been used by 5.6 million women since 2000, according to the FDA.

The reluctance of drugmakers to pause operations in Russia is being met with a growing chorus of criticism.